CVS Health Stock Soars 8.14% Ahead of Q1 Earnings

CVS Health's stock surged 8.14% in pre-market trading on May 1, 2025, ahead of its Q1 earnings report scheduled for release before the market opens.

CVS Health is anticipated to report a 5.4% year-on-year increase in revenue to $93.18 billion, with adjusted earnings expected to rise 27.5% to $1.67 per share. Analysts are optimistic about the company's ability to meet or exceed these estimates, citing improvements in Aetna's performance and strong demand for specialty drugs in the PBM segment.

Leerink Partners reiterated a Buy rating on CVS Health, boosting the price target to $79.00. Morgan Stanley also raised its price target to $80, maintaining an Overweight rating. However, Baird analysts do not expect guidance raises due to potential economic headwinds.

On TipRanks, CVS has a Strong Buy consensus based on 17 Buy and 3 Hold ratings, with the highest price target at $90. The company's Healthcare Benefits segment is expected to report better results in the first quarter of 2025, following a challenging fourth quarter.